What Ipamorelin is
Ipamorelin is a ghrelin receptor agonist and growth hormone secretagogue discussed for GH pulse signaling with a more selective profile than older secretagogues.
Ipamorelin is grouped under Fitness + Recovery / Longevity + Skin on PeptideFactCheck because it is often framed as a cleaner partner for CJC-1295 in optimization circles.
The useful starting point is to separate the molecule itself from the internet story around it. It has a reputation online as a cleaner GH secretagogue.
Why people keep looking it up
People use ipamorelin discussions for GH pulses, lean-body optimization, recovery, sleep, and aging claims.
Ipamorelin activates the ghrelin receptor pathway that can stimulate growth hormone release.
Ipamorelin tends to stay in the conversation because it touches a familiar public theme: ghrelin receptor, gh secretagogue, and ghsr. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
The hormone signal is not the same as proven long-term body composition or longevity benefit.
Human endocrine research exists, but it does not establish the broad anti-aging or body-composition claims often made online.
Preclinical and pharmacology data support receptor activity and endocrine effects.
Why this page carries the current tier: Some human endocrine signal, but claims exceed the clinical evidence base.
The current seed trail for Ipamorelin is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.
Safety, limits, and regulatory context
Long-term GH-axis manipulation, glucose handling, water retention, and product quality remain key concerns.
No FDA-approved ipamorelin drug product is listed in this V1 source trail.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Ipamorelin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Ipamorelin is CID 9831659. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 9831659
- Formula
- C38H49N9O5
- Molecular weight
- 711.9
- InChIKey
- NEHWBYHLYZGBNO-BVEPWEIPSA-N
Matched synonyms include Ipamorelin, 170851-70-4, NNC-26-0161, Y9M3S784Z6, Aib-His-D-2-Nal-D-Phe-Lys-NH2, NNC-260161, NNC 26-0161, Aib-His-2Nal-Phe-Lys-NH2.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Ipamorelin returns 2 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Ipamorelin returns 50 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.